Real-World Evidence in Oncology: Opportunities and Limitations
- PMID: 31872939
- PMCID: PMC7216461
- DOI: 10.1634/theoncologist.2019-0647
Real-World Evidence in Oncology: Opportunities and Limitations
Abstract
The analysis of real‐world evidence to answer clinical and policy‐relevant questions in the field of oncology has gained increased interest in recent years. This article highlights the strengths and weaknesses of the use of real‐world evidence in cancer care.
Keywords: Cancer treatments; Clinical trials; Real-world evidence.
Conflict of interest statement
References
-
- Karim S, Booth CM. Effectiveness in the absence of efficacy: Cautionary tales from real‐world evidence. J Clin Oncol 2019;37:1047–1050. - PubMed
-
- Booth CM, Karim S, Mackillop WJ. Real‐world data: Towards achieving the achievable in cancer care. Nat Rev Clin Oncol 2019;16:312–325. - PubMed
-
- Sherman RE, Anderson SA, Dal Pan GJ et al. Real‐world evidence ‐ What is it and what can it tell us? N Engl J Med 2016;375:2293–2297. - PubMed
-
- Tannock IF, Amir E, Booth CM et al. Relevance of randomised controlled trials in oncology. Lancet Oncol 2016;17:e560–e567. - PubMed
-
- Hall PS. Real‐world data for efficient health technology assessment. Eur J Cancer 2017;79:235–237. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
